129 related articles for article (PubMed ID: 31635489)
1. Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival.
Huang XF; Jian S; Lu JL; Shen KN; Feng J; Zhang CL; Tian Z; Wang JL; Lei WJ; Cao XX; Zhou DB; Liang ZY; Li J
Amyloid; 2020 Mar; 27(1):36-44. PubMed ID: 31635489
[No Abstract] [Full Text] [Related]
2. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
[TBL] [Abstract][Full Text] [Related]
3. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
[TBL] [Abstract][Full Text] [Related]
4. AL amyloidosis with a localized B cell neoplasia.
Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
[TBL] [Abstract][Full Text] [Related]
5. Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas.
Cutcutache I; Suzuki Y; Tan IB; Ramgopal S; Zhang S; Ramnarayanan K; Gan A; Lee HH; Tay ST; Ooi A; Ong CK; Bolthouse JT; Lane BR; Anema JG; Kahnoski RJ; Tan P; Teh BT; Rozen SG
Eur Urol; 2015 Jul; 68(1):77-83. PubMed ID: 25597018
[TBL] [Abstract][Full Text] [Related]
6. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing.
Kimura K; Tsukamoto S; Miyazaki K; Kawajiri-Manako C; Ishii A; Rahmutulla B; Fukuyo M; Oshima-Hasegawa N; Mitsukawa S; Takeda Y; Mimura N; Takeuchi M; Ohwada C; Iseki T; Matsusaka K; Sanada M; Yokote K; Kaneda A; Ishida T; Suzuki K; Nakaseko C; Sakaida E
Exp Hematol; 2021 Sep; 101-102():34-41.e4. PubMed ID: 34411686
[TBL] [Abstract][Full Text] [Related]
7. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers in Immunoglobulin Light Chain Amyloidosis.
Kufová Z; Sevcikova T; Growkova K; Vojta P; Filipová J; Adam Z; Pour L; Penka M; Rysava R; Němec P; Brozova L; Vychytilova P; Jurczyszyn A; Grosicki S; Barchnicka A; Hajdúch M; Simicek M; Hájek R
Klin Onkol; 2017; 30(Supplementum2):60-67. PubMed ID: 28903572
[TBL] [Abstract][Full Text] [Related]
9. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
10. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
11. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival.
Visser E; Franken IA; Brosens LAA; de Leng WWJ; Strengman E; Offerhaus JA; Ruurda JP; van Hillegersberg R
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859360
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment.
Muchtar E; Jevremovic D; Dispenzieri A; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Chakraborty R; Zeldenrust S; Kumar SK; Kyle RA; Rajkumar SV; Gertz MA
Blood; 2017 Jan; 129(1):82-87. PubMed ID: 27729322
[TBL] [Abstract][Full Text] [Related]
13. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
15. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
[TBL] [Abstract][Full Text] [Related]
16. Cancer-Associated Mutations in Endometriosis without Cancer.
Anglesio MS; Papadopoulos N; Ayhan A; Nazeran TM; Noë M; Horlings HM; Lum A; Jones S; Senz J; Seckin T; Ho J; Wu RC; Lac V; Ogawa H; Tessier-Cloutier B; Alhassan R; Wang A; Wang Y; Cohen JD; Wong F; Hasanovic A; Orr N; Zhang M; Popoli M; McMahon W; Wood LD; Mattox A; Allaire C; Segars J; Williams C; Tomasetti C; Boyd N; Kinzler KW; Gilks CB; Diaz L; Wang TL; Vogelstein B; Yong PJ; Huntsman DG; Shih IM
N Engl J Med; 2017 May; 376(19):1835-1848. PubMed ID: 28489996
[TBL] [Abstract][Full Text] [Related]
17. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
19. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
20. Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management.
Baumgart JV; Stuhlmann-Laeisz C; Hegenbart U; Nattenmüller J; Schönland S; Krüger S; Behrens HM; Röcken C
Virchows Arch; 2018 Nov; 473(5):627-637. PubMed ID: 30136180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
